Accrued Liabilities, Current in USD of Anixa Biosciences Inc from Q3 2010 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Anixa Biosciences Inc quarterly Accrued Liabilities, Current history and change rate from Q3 2010 to Q2 2025.
  • Anixa Biosciences Inc Accrued Liabilities, Current for the quarter ending July 31, 2025 was $1.75M, a 4.35% increase year-over-year.
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Change (%)

Anixa Biosciences Inc Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 $1.75M +$73K +4.35% Jul 31, 2025 10-Q 2025-09-10
Q1 2025 $1.57M +$156K +11.1% Apr 30, 2025 10-Q 2025-05-28
Q4 2024 $1.36M +$121K +9.74% Jan 31, 2025 10-Q 2025-03-11
Q3 2024 $1.95M +$176K +9.94% Oct 31, 2024 10-Q 2025-09-10
Q2 2024 $1.68M -$34K -1.99% Jul 31, 2024 10-Q 2024-09-06
Q1 2024 $1.41M +$117K +9.05% Apr 30, 2024 10-Q 2024-06-04
Q4 2023 $1.24M +$167K +15.5% Jan 31, 2024 10-Q 2024-03-12
Q3 2023 $1.77M +$44K +2.55% Oct 31, 2023 10-K 2025-01-10
Q2 2023 $1.71M +$514K +42.9% Jul 31, 2023 10-Q 2023-09-06
Q1 2023 $1.29M +$236K +22.3% Apr 30, 2023 10-Q 2023-06-14
Q4 2022 $1.08M -$167K -13.4% Jan 31, 2023 10-Q 2023-03-17
Q3 2022 $1.73M +$631K +57.6% Oct 31, 2022 10-K 2024-01-16
Q2 2022 $1.2M +$208K +21% Jul 31, 2022 10-Q 2022-09-09
Q1 2022 $1.06M +$78.1K +7.98% Apr 30, 2022 10-Q 2022-06-10
Q4 2021 $1.24M +$269K +27.7% Jan 31, 2022 10-Q 2022-03-11
Q3 2021 $1.1M +$194K +21.5% Oct 31, 2021 10-K 2023-01-04
Q2 2021 $990K +$174K +21.3% Jul 31, 2021 10-Q 2021-09-01
Q1 2021 $979K +$129K +15.1% Apr 30, 2021 10-Q 2021-06-10
Q4 2020 $973K +$268K +38% Jan 31, 2021 10-Q 2021-03-11
Q3 2020 $901K +$5.53K +0.62% Oct 31, 2020 10-K 2022-01-04
Q2 2020 $816K -$60.1K -6.86% Jul 31, 2020 10-Q 2020-09-08
Q1 2020 $850K -$27.7K -3.15% Apr 30, 2020 10-Q 2020-06-09
Q4 2019 $705K -$9.11K -1.28% Jan 31, 2020 10-Q 2020-03-09
Q3 2019 $895K +$212K +31.1% Oct 31, 2019 10-K 2021-01-07
Q2 2019 $876K +$166K +23.3% Jul 31, 2019 10-Q 2019-09-06
Q1 2019 $878K -$10.3K -1.16% Apr 30, 2019 10-Q 2019-06-12
Q4 2018 $714K +$44.5K +6.65% Jan 31, 2019 10-Q 2019-03-13
Q3 2018 $683K +$274K +66.9% Oct 31, 2018 10-K 2020-01-09
Q2 2018 $710K Jul 31, 2018 10-Q 2018-09-07
Q1 2018 $888K Apr 30, 2018 10-Q 2018-06-11
Q4 2017 $670K Jan 31, 2018 10-Q 2018-03-09
Q3 2017 $409K +$314K +328% Oct 31, 2017 10-K 2019-01-11
Q3 2016 $95.5K Oct 31, 2016 10-K 2018-01-09
Q2 2013 $691K +$561K +432% Jul 31, 2013 10-Q/A 2013-09-20
Q1 2013 $610K +$470K +336% Apr 30, 2013 10-Q/A 2013-06-19
Q4 2012 $582K +$421K +260% Jan 31, 2013 10-Q/A 2013-03-25
Q3 2012 $331K +$245K +285% Oct 31, 2012 10-Q/A 2013-09-20
Q2 2012 $130K +$54.8K +73.1% Jul 31, 2012 10-Q 2012-09-14
Q1 2012 $140K Apr 30, 2012 10-Q 2012-06-14
Q4 2011 $162K Jan 31, 2012 10-Q 2012-03-16
Q3 2011 $85.8K -$8.66K -9.17% Oct 31, 2011 10-K 2013-01-29
Q2 2011 $75K Jul 31, 2011 10-Q/A 2011-10-14
Q3 2010 $94.4K Oct 31, 2010 10-K 2012-01-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.